Camp4 Therapeutics vs Entrada Therapeutics
CAMP and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAMP and TRDA compare
Camp4 Therapeutics is the larger company, worth 1.2 times as much as Entrada Therapeutics ($264M against $212M).
Camp4 Therapeutics grew revenue faster over the last twelve months (39.9% versus −93.5% for Entrada Therapeutics).
Camp4 Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2276% compared with −4058% at Entrada Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAMP | TRDA |
|---|---|---|
| Size and price | ||
| Market cap | $264M | $212M |
| Share price | $4.20 | $5.44 |
| Change, 1 year | 0.96% | −25.1% |
| Change, 5 years | −98.2% | −83.4% |
| Beta (5Y) | 2.74 | 0.97 |
| Employees | 48 | 152 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 49.5× (better) | 53.3× |
| P/B | 2.5× | 1.1× (better) |
| FCF yield | −10.0% (better) | −64.4% |
| Fair value | $2.59 | – |
| Margin of safety | −62.3% | – |
| Growth | ||
| Revenue growth (TTM) | 39.9% (better) | −93.5% |
| Profitability | ||
| Operating margin | −1001% (better) | −4304% |
| Net margin | −2276% (better) | −4058% |
| FCF margin | −496% (better) | −3428% |
| Return on equity | −146% | −59.9% (better) |
| Return on invested capital | – | −1406% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.42 | 7.85 (better) |
| Altman Z-score | 1.67 (better) | −1.53 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 66.5% | 75.6% |
| Held by insiders | 21.7% | 14.8% |
| Insider net buying, 12 months | −$2.4M (better) | −$11.5M |
| Short interest, % of float | 6.6% | 8.5% |
Go deeper
- CAMP stock overview
- CAMP income statement
- CAMP valuation and score
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.